surmount-1 trial tirzepatide obesity without diabetes (ZEPBOUND) Approved for Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or With respect to the SURMOUNT-MAINTAIN
Description
This placebo figure is consistent with average weight loss totals associated with dietary changes
The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who have established cardiovascular disease or indicators of high cardiovascular risk, or when weight loss is a priority
Third , the combination lacks robust safety data from controlled trials, meaning potential synergistic effects or unexpected interactions remain inadequately characterized
Make sure a clinician reviews your request Your health is taken very seriously, which is why our UK-approved prescribers review every message and request that you submit
Final Check: Ensure there are no clumps or particles left before storing the vial in the refrigerator
Diastolic blood pressure was significantly reduced in Study 1 but not in Study 2
